Filtered By:
Condition: Ischemic Stroke
Drug: Fluoxetine

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 46 results found since Jan 2013.

Efficacy of Fluoxetine for Post-Ischemic Stroke Depression in Tanzania
Post-stroke fluoxetine trials are primarily conducted in high-income countries. We characterize post-ischemic stroke depression in fluoxetine-treated and -untreated study participants in urban Tanzania.
Source: Journal of Stroke and Cerebrovascular Diseases - November 2, 2021 Category: Neurology Authors: Dylan R. Rice, Kigocha Okeng'o, Emmanuel Massawe, Seif Ismail, Notburga A. Mworia, Faraja Chiwanga, Boniface Kapina, Michael Wasserman, Farrah J. Mateen Source Type: research

MEASURING AMBULATION, MOTOR, AND BEHAVIORAL OUTCOMES WITH POST-STROKE FLUOXETINE IN TANZANIA: THE Phase II MAMBO TRIAL
We test the safety of fluoxetine post-ischemic stroke in Sub-Saharan Africa. Adults with acute ischemic stroke, seen
Source: Journal of Stroke and Cerebrovascular Diseases - March 20, 2022 Category: Neurology Authors: Emmanuel Massawe, Notburga A. Mworia, Seif Ismail, Dylan R. Rice, Andre C. Vogel, Boniface Kapina, Novath Mukyanuzi, Deus C. Buma, Jef Gluckstein, Michael Wasserman, Susan E. Fasoli, Faraja Chiwanga, Farrah J. Mateen, Kigocha Okeng'o Source Type: research

Effects of Fluoxetine on Neural Functional Prognosis after Ischemic Stroke: A Randomized Controlled Study in China
We investigated the effects of fluoxetine on the short-term and long-term neural functional prognoses after ischemic stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - January 25, 2016 Category: Neurology Authors: Yi-Tao He, Bing-Shan Tang, Zhi-Li Cai, Si-Ling Zeng, Xin Jiang, Yi Guo Source Type: research

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
CONCLUSIONS: We found no reliable evidence that SSRIs should be used routinely to promote recovery after stroke. Meta-analysis of the trials at low risk of bias indicate that SSRIs do not improve recovery from stroke. We identified potential improvements in disability only in the analyses which included trials at high risk of bias. A further meta-analysis of large ongoing trials will be required to determine the generalisability of these findings. PMID: 31769878 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - November 25, 2019 Category: General Medicine Authors: Legg LA, Tilney R, Hsieh CF, Wu S, Lundström E, Rudberg AS, Kutlubaev MA, Dennis M, Soleimani B, Barugh A, Hackett ML, Hankey GJ, Mead GE Tags: Cochrane Database Syst Rev Source Type: research

Selective serotonin reuptake inhibitors to improve outcome in acute ischemic stroke: possible mechanisms and clinical evidence
ConclusionIn addition to the need of comprehensive‐clinical evidence, further elucidation of the beneficial mechanisms whereby SSRIs may improve structural and functional recovery from ischemic‐brain damage is needed to form a basis for translation into clinical practice. Several clinical studies have indicated that selective serotonin reuptake Inhibitors (SSRIs) administered after acute ischemic stroke can improve clinical recovery independently of depression. However, data from confirmatory trials in large study populations are lacking and the underlying mechanisms are incompletely understood. This review summarizes...
Source: Brain and Behavior - September 1, 2015 Category: Neurology Authors: Timo Siepmann, Ana Isabel Penzlin, Jessica Kepplinger, Ben Min‐Woo Illigens, Kerstin Weidner, Heinz Reichmann, Kristian Barlinn Tags: Review Source Type: research

Neuroplasticity and behavioral effects of  fluoxetine after experimental stroke.
Neuroplasticity and behavioral effects of fluoxetine after experimental stroke. Restor Neurol Neurosci. 2017 Aug 24;: Authors: Sun Y, Sun X, Qu H, Zhao S, Xiao T, Zhao C Abstract The brain can undergo self-repair and has the ability to compensate for functions lost after a stroke. The plasticity of the ischemic brain is influenced by several factors including aging and pharmacotherapy. Fluoxetine is an antidepressant which enhances serotonergic neurotransmission through selective inhibition of neuronal reuptake of serotonin. In clinical practice, fluoxetine alleviates the symptoms of post-stroke depre...
Source: Restorative Neurology and Neuroscience - September 1, 2017 Category: Neurology Tags: Restor Neurol Neurosci Source Type: research

The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial.
CONCLUSION: There was no significant difference between citalopram and fluoxetine in facilitating post-stroke motor recovery in ischemic stroke patients. However, compared with a placebo, both drugs improved post-stroke motor function. PMID: 29783900 [PubMed - as supplied by publisher]
Source: Clinical Rehabilitation - May 1, 2018 Category: Rehabilitation Authors: Asadollahi M, Ramezani M, Khanmoradi Z, Karimialavijeh E Tags: Clin Rehabil Source Type: research

Does the Initiation of Fluoxetine Postacute Stroke Result in Improved Functional Recovery?: A Critically Appraised Topic
Conclusion: Among patients with stroke, early initiation of fluoxetine did not result in improved functional recovery. Lower rates of depression were observed in the fluoxetine-treated group; however these patients experienced higher rates of bone fracture.
Source: The Neurologist - May 1, 2021 Category: Neurology Tags: Critically Appraised Topics Source Type: research

MAMBO: Measuring ambulation, motor, and behavioral outcomes with post-stroke fluoxetine in Tanzania: Protocol of a phase II clinical trial
Sub-Saharan Africa has a high stroke incidence and post-stroke morbidity. An inexpensive pharmacological treatment for stroke recovery would be beneficial to patients in the region. Fluoxetine, currently on the World Health Organization Essential Medicines List, holds promise as a treatment for motor recovery after ischemic stroke, but its effectiveness is controversial and untested in this context in Sub-Saharan Africa.
Source: Journal of the Neurological Sciences - November 5, 2019 Category: Neurology Authors: AndreC. Vogel, Kigocha Okeng'o, Faraja Chiwanga, Seif Sharif Ismail, Deus Buma, Lindsay Pothier, Farrah J. Mateen Source Type: research

Boon or Bane? Using Antidepressants After Stroke
Depression affects 1 in every 3 adults within the first six months after a stroke [1]. In addition to being common, it increases the burden of illness and hinders recovery from stroke [2], so that adequate measures to treat and prevent depression in this population are needed. The results of the fluoxetine in motor recovery of patients with acute ischaemic stroke (FLAME) trial (n  = 118) showed that stroke survivors treated with fluoxetine had better motor function than their counterparts treated with placebo for 3 months [3].
Source: Maturitas - February 24, 2021 Category: Primary Care Authors: Osvaldo P. Almeida, Joshua Jones, Graeme J. Hankey, Maree Hackett Source Type: research

Effect of using fluoxetine at different time windows on neurological functional prognosis after ischemic stroke.
CONCLUSIONS: In patients with ischemic stroke, early administration of fluoxetine may improve the neurological functional prognosis. PMID: 26923613 [PubMed - as supplied by publisher]
Source: Restorative Neurology and Neuroscience - March 1, 2016 Category: Neurology Tags: Restor Neurol Neurosci Source Type: research

Fluoxetine for Stroke: A Mixed Bag of Outcomes
J Clin Psychiatry. 2021 Jun 8;82(3):21f14106. doi: 10.4088/JCP.21f14106.ABSTRACTStroke is the leading neurologic cause of burden operationalized in terms of disability-adjusted life-years. After stroke, motor deficits, cognitive deficits, and depression cause loss of independence, disability, decreased functioning, and reduced quality of life; these persist into the long term. There are theoretical grounds to consider that, through neuroplasticity and other mechanisms, such impairments can be prevented or attenuated by the early introduction of a selective serotonin reuptake inhibitor such as fluoxetine. However, a recent ...
Source: Journal of Clinical Psychiatry - June 9, 2021 Category: Psychiatry Authors: Chittaranjan Andrade Source Type: research